

Vitrolife Group to host Capital Markets Day on 12 December 2023

Vitrolife AB (publ) today announced that it will host a Capital Markets Day presentation for the investment community on 12 December 2023, 10:00-15:30 CET in Stockholm.

Bronwyn Brophy, Chief Executive Officer, and Patrik Tolf, Chief Financial Officer, will be joined by leading experts and practitioners in the reproductive health industry to share their thoughts on the future of infertility care around the world. The Executive Management team will set out the new corporate strategy to drive sustainable, profitable growth capitalising on the mega market trends and leveraging the Vitrolife Group core strengths and capabilities. They will also discuss their plans to bring more much needed innovation to the reproductive health market.

For further detail on the Capital Markets Day, including the agenda and speakers, please visit <https://www.vitrolifegroup.com/en/investor-relations/presentations/capital-markets-update-2023>. We welcome in-person attendance, where you can also explore the Vitrolife Group marketplace, at Hotel At Six, Brunkebergstorg 6, Stockholm, Sweden. Please RSVP by contacting investors@vitrolife.com no later than 7 December 2023. Access to a live webcast will be available on our website, beginning 15 minutes prior to the start time of the presentation, and a replay will be available following the event.

Gothenburg, 30 November 2023
VITROLIFE AB (publ)

Contact:

Patrik Tolf, CFO, phone +46 (0)31 766 90 21

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden.

Vitrolife Group's products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a healthy baby. The Vitrolife AB (publ) share is listed on the Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.